Zou Kelly H, Berger Marc L
Viatris Inc., Canonsburg, PA 15317, USA.
AI4Purpose Inc., New York, NY 10016, USA.
Bioengineering (Basel). 2024 Aug 2;11(8):784. doi: 10.3390/bioengineering11080784.
The use of real-world data (RWD) for healthcare decision-making is complicated by concerns regarding whether RWD is fit-for-purpose or is of sufficient validity to support the creation of credible RWE. An efficient mechanism for screening the quality of RWD is needed as regulatory agencies begin to use real-world evidence (RWE) to inform decisions about treatment effectiveness and safety. First, we provide an overview of RWD and RWE. Data quality frameworks (DQFs) in the US and EU were examined, including their dimensions and subdimensions. There is some convergence of the conceptual DQFs on specific assessment criteria. Second, we describe a list of screening criteria for assessing the quality of RWD sources. The curation and analysis of RWD will continue to evolve in light of developments in digital health and artificial intelligence (AI). In conclusion, this paper provides a perspective on the utilization of RWD and RWE in healthcare decision-making. It covers the types and uses of RWD, data quality frameworks (DQFs), regulatory landscapes, and the potential impact of RWE, as well as the challenges and opportunities for the greater leveraging of RWD to create credible RWE.
将真实世界数据(RWD)用于医疗保健决策,因人们担心RWD是否适用于特定目的或是否具有足够的有效性以支持创建可靠的真实世界证据(RWE)而变得复杂。随着监管机构开始使用真实世界证据(RWE)来为有关治疗有效性和安全性的决策提供信息,需要一种有效的机制来筛选RWD的质量。首先,我们概述了RWD和RWE。研究了美国和欧盟的数据质量框架(DQF),包括其维度和子维度。概念性DQF在特定评估标准上存在一些趋同之处。其次,我们描述了一份用于评估RWD来源质量的筛选标准清单。鉴于数字健康和人工智能(AI)的发展,RWD的管理和分析将不断发展。总之,本文提供了关于在医疗保健决策中利用RWD和RWE的观点。它涵盖了RWD的类型和用途、数据质量框架(DQF)、监管环境以及RWE的潜在影响,以及更大程度利用RWD以创建可靠RWE的挑战和机遇。